Insulet Corporation
Corporate brand
UnclaimedMedical device company focused on tubeless insulin delivery and diabetes management systems.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Insulet Corporation is a United States medical-device company focused on insulin delivery and diabetes-management technology. Founded in 2000 and headquartered in Acton, Massachusetts, the company is best known for the Omnipod family of wearable, tubeless insulin-delivery systems. Unlike conventional insulin-pump arrangements that generally use a pump connected to the body by tubing, Omnipod systems are designed around a small wearable device, commonly called a Pod, that delivers insulin through a cannula while being managed through a compatible controller or, where supported, a connected mobile device. The company’s core business is centered on people who require insulin therapy, particularly individuals with type 1 diabetes and insulin-dependent type 2 diabetes. Its products combine disposable wearable delivery hardware, controllers or software interfaces, and supporting digital tools. This places Insulet at the intersection of medical devices, connected health, diabetes technology, and consumer-oriented health-care design. The company’s differentiation is strongly associated with the tubeless format, portability, and efforts to simplify daily insulin administration compared with traditional pump systems. Insulet’s principal commercial platform is Omnipod. The product family has included systems with different generations of Pods, communication methods, controllers, and integration capabilities. The brand’s portfolio has also developed alongside continuous glucose monitoring and automated insulin-delivery ecosystems, although the precise features and availability of particular products vary by market and regulatory authorization. Insulet therefore operates in a highly regulated environment in which product launches, software updates, labeling, reimbursement arrangements, and market expansion depend on approval and local health-care conditions. The company sells through a combination of direct and commercial health-care channels, serving customers in the United States and selected international markets including Europe, Canada, and Australia. Its business model is tied not only to initial system adoption but also to recurring demand for replacement Pods and related supplies. This creates an installed-base component to the business, while also requiring dependable manufacturing, distribution, customer support, and reimbursement access. Insulet is a publicly listed company whose shares trade on Nasdaq under the ticker PODD. Its corporate identity is closely linked to the Omnipod brand rather than to a broad collection of unrelated medical products. The company remains active and continues to position itself around wearable insulin delivery and technology intended to make insulin therapy more convenient, connected, and adaptable to patients’ daily lives.
History
Insulet was established in 2000 in the United States with a focus on developing an alternative to conventional insulin-pump delivery. The company’s central concept was a wearable, tubeless system that could deliver insulin through a disposable Pod rather than relying on a pump connected to the user by an external tube. This design direction shaped the company’s identity and became the foundation of the Omnipod product family. Over time, Insulet developed its business around the commercialization and expansion of Omnipod systems. The platform combined a wearable insulin-delivery device with a controller or other user interface, allowing patients to operate the system while wearing the Pod on the body. The company’s products were intended primarily for people with insulin-dependent diabetes, including type 1 diabetes and insulin-dependent type 2 diabetes. As the portfolio matured, successive generations emphasized usability, connectivity, portability, and compatibility with broader diabetes-management workflows. The evolution of the Omnipod platform also reflected wider changes in diabetes technology. Insulin pumps increasingly became connected devices rather than isolated mechanical products, and patients and clinicians sought closer integration among insulin delivery, continuous glucose monitoring, mobile software, and automated dosing. Insulet consequently developed and marketed product generations with updated controllers, communications capabilities, and automation features, subject to regulatory clearance and market-specific availability. The company’s commercial model is distinctive within medical devices because the system includes recurring-use disposable Pods. Each new Pod supports continuing use of the platform, making manufacturing capacity, supply reliability, customer education, reimbursement, and service important parts of the overall business. Insulet has expanded beyond its United States base into selected international markets, including Europe, Canada, and Australia, while operating within differing regulatory and reimbursement systems. Insulet became a publicly traded company and uses the Nasdaq ticker PODD. Its corporate and product history remains closely associated with Omnipod, which functions as the company’s principal commercial platform and consumer-facing identity. Rather than competing across many unrelated medical categories, Insulet has concentrated its technology, manufacturing, and commercial efforts on insulin delivery and diabetes management. The company is active and continues to develop its wearable and connected-device approach for people who use insulin therapy.
- 2000
Insulet founded
[1]Insulet was established in the United States to develop insulin-delivery technology, with a strategic focus on a wearable, tubeless approach.
Omnipod becomes the company’s core platform
[1]Insulet built its commercial identity around the Omnipod family of wearable insulin-delivery systems and recurring-use Pods.
Expansion into connected and automated insulin delivery
[1]Later Omnipod generations added updated controllers, connectivity, and automated insulin-delivery capabilities where authorized.
Products and positioning
A diabetes-technology and medical-device company positioned around wearable, tubeless insulin delivery and connected diabetes management.
Tubeless insulin-delivery system
Omnipod
Omnipod is Insulet’s principal product family. It uses a wearable, disposable Pod to deliver insulin through a small infusion cannula, avoiding the external tubing associated with many traditional insulin pumps. Depending on the model and market, the system is operated through a dedicated controller, mobile software, or an automated delivery configuration. The platform is intended for people who require insulin therapy and is supported by related software, supplies, education, and customer services.
Connected tubeless insulin pump system
Omnipod DASH
Omnipod DASH is a connected generation of the Omnipod platform designed to provide tubeless insulin delivery through wearable Pods and a dedicated management interface. Its role in the portfolio is to support day-to-day pump operation while adding modern connectivity and user-interface features. Availability, labeling, and supported integrations depend on the relevant market and regulatory authorization.
Automated insulin-delivery system
Omnipod 5 Automated Delivery System
Omnipod 5 is an automated insulin-delivery product in the Omnipod family. It combines wearable Pod-based insulin delivery with software and glucose-informed automation intended to adjust insulin delivery within the system’s authorized parameters. The product represents Insulet’s move from a tubeless pump platform toward connected and automated diabetes management. Features and availability vary by market and applicable regulatory approvals.
Recent events
Reported
Insulet and Dexcom announce Omnipod Horizon integration agreement[2]
Insulet and Dexcom announced a global commercialization agreement to combine Dexcom continuous glucose monitoring technology with Insulet’s Omnipod Horizon automated insulin delivery system. The system is intended to use Dexcom G6 and next-generation G7 sensor values, once available.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/insulet · Editorial policy · How profiles are compiled